Retroperitoneal NeoplasmsNCT07915895
Retroperitoneal Tumor Registry
An observational study of Retroperitoneal Neoplasms, run by The First Hospital of Jilin University at 1 site in China.
Trial summary
This is an observational, real-world registry study. The RETROR registry aims to establish a clinical database for patients with retroperitoneal tumors. We will systematically collect demographic information, comorbidities, preoperative imaging findings, perioperative parameters, pathological outcomes, adjuvant… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Retroperitoneal Neoplasms
- How many people
- 200 participants
- Where
- 1 siteChina
- Study dates
- 1 Dec 2024to 1 Dec 2027
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: This is a single-center real-world registry study. The study population consists of patients with preoperative imaging or pathological diagnosis of retroperitoneal tumors, without age or gender restriction. Clinical, imaging, pathological, treatment and follow-up data will be collected prospectively.
Who may be able to join
- Patients with preoperative imaging or pathological diagnosis of retroperitoneal tumors, with no restriction on age and gender.
Who cannot join
- Patients with psychiatric or neurological disorders who cannot express their will properly.
- Patients who are unable to understand the study protocol and refuse to participate or sign the informed consent form.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The First Hospital of Jilin University
Changchun, Jilin, 130021
Quan Wang, MD, +86-431-81875602, wquan@jlu.edu.cn
Luyao Zhang, MD, +86-431-81875601
About this study
Official title: Retroperitoneal Tumor Registry: A Real-world Cohort Study of Clinical Features, Surgical Outcomes and Long-term Survival
This is an observational, real-world registry study. The RETROR registry aims to establish a clinical database for patients with retroperitoneal tumors. We will systematically collect demographic information, comorbidities, preoperative imaging findings, perioperative parameters, pathological outcomes, adjuvant treatment, surgical complications, recurrence, metastasis, and long-term survival data. The registry will summarize clinical features, evaluate surgical outcomes, and explore prognostic factors of retroperitoneal tumors. Written informed consent will be obtained from all participants prior to enrollment.
- Conditions
- Retroperitoneal Neoplasms
- Keywords
- Retroperitoneal tumor, Retroperitoneal sarcoma
- Medical subject headings
- Retroperitoneal Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
Time from diagnosis to death from any cause
Measured: Up to 5 years after enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Nov 2026
- Study start1 Dec 2024
- Primary completion1 Dec 2027 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Retroperitoneal NeoplasmsStudies of the same condition, open and under way.
- More trials run by The First Hospital of Jilin UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- The First Hospital of Jilin University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Quan Wang, The First Hospital of Jilin University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07915895
- Sponsor's protocol ID
- RETROR
- Status last verified
- Oct 2026
- First submitted
- 30 Oct 2026
- Last updated
- 4 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared. Data sharing is restricted by institutional policy and patient privacy protection requirements. Aggregated study results may be published in peer-reviewed journals.
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Retroperitoneal Tumor Registry: A Real-world Cohort Study of Clinical Features, Surgical Outcomes and Long-term Survival
- ClinicalTrials.gov ID
- NCT07915895
- Acronym / sponsor ID
- RETROR
- Conditions
- Retroperitoneal Neoplasms
- Keywords
- Retroperitoneal tumor, Retroperitoneal sarcoma
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- The First Hospital of Jilin UniversityUniversity, hospital or other
- Study start
- 1 Dec 2024 (actual)
- Primary completion
- 1 Dec 2027 (estimated)
- Study completion
- 1 Dec 2027 (estimated)
- First posted
- 4 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an observational, real-world registry study. The RETROR registry aims to establish a clinical database for patients with retroperitoneal tumors. We will systematically collect demographic information, comorbidities, preoperative imaging findings, perioperative parameters, pathological outcomes, adjuvant treatment, surgical complications, recurrence, metastasis, and long-term survival data. The registry will summarize clinical features, evaluate surgical outcomes, and explore prognostic factors of retroperitoneal tumors. Written informed consent will be obtained from all participants prior to enrollment.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- This is a single-center real-world registry study. The study population consists of patients with preoperative imaging or pathological diagnosis of retroperitoneal tumors, without age or gender restriction. Clinical, imaging, pathological, treatment and follow-up data will be collected prospectively.
Key inclusion criteria (1 listed)
- Patients with preoperative imaging or pathological diagnosis of retroperitoneal tumors, with no restriction on age and gender.
Key exclusion criteria (2 listed)
- Patients with psychiatric or neurological disorders who cannot express their will properly.
- Patients who are unable to understand the study protocol and refuse to participate or sign the informed consent form.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall Survival
Time frame: Up to 5 years after enrollment
Time from diagnosis to death from any cause
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared. Data sharing is restricted by institutional policy and patient privacy protection requirements. Aggregated study results may be published in peer-reviewed journals.
Related trials for Retroperitoneal Neoplasms
RecruitingPhase 2
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Gastric Adenocarcinoma, Stomach Neoplasms
RecruitingPhase 3
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Retroperitoneal Sarcoma, Liposarcoma
Not yet recruiting
Patient Reported Outcomes and Different Renal Artery Clamping Techniques During Robot Assisted Kidney Resection
Renal Cell Carcinoma (Kidney Cancer)
Not yet recruitingPhase 2
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum
RecruitingPhase 1
Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy (SBRT) in Participants With Cancer-Related Celiac Pain
Pancreatic Cancer, Retroperitoneal Pain Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Retroperitoneal Neoplasms, run by The First Hospital of Jilin University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (time frame: Up to 5 years after enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.